Description:

Nilotinib is a potent, selective tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia. It works by blocking the BCR-ABL protein, which is produced by abnormal chromosomes in cancer cells and promotes their growth. By inhibiting this enzyme, Nilotinib helps slow or stop the progression of the disease. It is primarily used in the management of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

Nilotinib selectively inhibits the BCR-ABL tyrosine kinase, including several mutant forms of BCR-ABL, and other kinases such as c-Kit and PDGFR. This inhibition blocks proliferation and induces apoptosis in leukemia cells that express BCR-ABL.

Chronic phase and accelerated phase Ph+ chronic myeloid leukemia (CML) in adult patients who are resistant or intolerant to prior therapy including imatinib
First-line treatment of newly diagnosed adult patients with Ph+ CML in the chronic phase